Welcome to our dedicated page for Karyopharm Therapeutics news (Ticker: KPTI), a resource for investors and traders seeking the latest updates and insights on Karyopharm Therapeutics stock.
Karyopharm Therapeutics Inc. reports developments tied to its commercial oncology business and selinexor-based drug development. The company markets XPOVIO (selinexor) and reports U.S. product revenue, license and other revenue, liquidity, and operating updates alongside its periodic financial results.
Recurring KPTI news also covers late-stage clinical programs evaluating selinexor in cancer indications, including the Phase 3 SENTRY trial in myelofibrosis and the Phase 3 XPORT-EC-042 trial in endometrial cancer. Company updates include clinical data presentations, regulatory-development disclosures, equity inducement grants under Nasdaq rules, financing activity, and other corporate and capital-structure matters.
Karyopharm (Nasdaq: KPTI) reported Phase 3 SENTRY trial results of selinexor plus ruxolitinib in JAK inhibitor‑naïve myelofibrosis, presented as a late‑breaking oral session at ASCO 2026 with simultaneous publication in the Journal of Clinical Oncology.
The combination significantly improved SVR35 at week 24 versus ruxolitinib alone (49.8% vs 28.0%; p<0.0001), showed a favorable overall survival hazard ratio of 0.43, evidence of ≥20% VAF reductions, and maintained a safety profile consistent with known selinexor and ruxolitinib effects. The co‑primary symptom endpoint (Abs‑TSS) did not reach statistical significance.
Karyopharm Therapeutics (Nasdaq: KPTI) granted an inducement equity award to a newly hired employee under its 2022 Inducement Stock Incentive Plan. The award consists of 1,200 restricted stock units (RSUs), granted on May 31, 2026, in accordance with Nasdaq Listing Rule 5635(c)(4).
The RSUs vest over three years, with 33 1/3% vesting on each anniversary of the grant date, subject to the employee’s continued service with Karyopharm.
Karyopharm (Nasdaq:KPTI) will host an investor conference call on June 2, 2026 at 2:00 p.m. ET to discuss the Phase 3 SENTRY trial of selinexor plus ruxolitinib in myelofibrosis, following an oral presentation at the 2026 ASCO Annual Meeting.
The event features Karyopharm's senior management and Dr. John Mascarenhas, SENTRY principal investigator. Investors can join via phone or a live audio webcast with slides under “Events & Presentations” in the investor section of Karyopharm’s website, with an archived replay available about two hours after the call.
Karyopharm (Nasdaq: KPTI) announced that senior management will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on June 4, 2026, at 8:10 a.m. ET in New York.
A live webcast and replay will be available in the Investors & Media section of Karyopharm's website.
Karyopharm (Nasdaq: KPTI) reported first quarter 2026 total revenue of $35.1 million, including $29.2 million U.S. XPOVIO net product revenue, and reaffirmed 2026 revenue guidance of $130–$150 million. The company completed enrollment in its Phase 3 endometrial cancer trial and reported pivotal Phase 3 SENTRY myelofibrosis results.
Karyopharm (Nasdaq: KPTI) announced that senior management will participate in two May 2026 investor conferences via fireside chats: the H.C. Wainwright 4th Annual BioConnect Investor Conference and the RBC 2026 Global Healthcare Conference, both on May 19, 2026.
Live webcasts and replays will be available in the Events & Presentations section of Karyopharm's investor relations website.
Karyopharm (Nasdaq: KPTI) will report first quarter 2026 financial results on Thursday, May 14, 2026. Management will host a conference call and live audio webcast at 8:00 a.m. ET to discuss results and company updates. Slides and an archived webcast will be available on the investor website approximately two hours after the event.
Karyopharm (Nasdaq: KPTI) said its late-breaking abstract from the Phase 3 SENTRY trial in myelofibrosis was accepted for an oral presentation at the ASCO 2026 Annual Meeting in Chicago.
The presentation covers 60 mg selinexor plus ruxolitinib in JAK inhibitor–naïve myelofibrosis (Abstract LBA6500), scheduled for June 2, 2026 at 9:45 a.m.–12:45 p.m. CT. According to the company, the presentation copy will be posted after the event under "Publications and Presentations" in Investor Relations.
Karyopharm (Nasdaq: KPTI) entered a private placement with RA Capital expected to raise approximately $30 million in gross proceeds, with an additional $44 million/b) if accompanying warrants are exercised in full. The financing includes 1,030,354 common shares, 3,391,164 pre-funded warrants, and warrants for 4,421,518 shares.The offering was priced at-the-market under Nasdaq rules and is expected to close on or about March 26, 2026. Net proceeds plus existing liquidity are expected to fund operations into late Q3 2026. Proceeds are for general corporate purposes and planned clinical trial activities.
Karyopharm (Nasdaq: KPTI) reported topline Phase 3 SENTRY results in frontline myelofibrosis (n=353). The trial met its first co-primary endpoint: SVR35 50% vs 28% at Week 24 (one-sided p<0.0001) for selinexor plus ruxolitinib. The Abs-TSS symptom endpoint was not met. A promising overall survival signal (HR 0.43) was observed; safety showed higher grade 3+ TEAEs with the combination.